Search for episodes from Cytokine Signalling Forum with a specific topic:

Latest episodes from Cytokine Signalling Forum

Discussing axSpA: JAKi cycling and long-term safety of bimekizumab in patients with axSpA or PsA

Play Episode Listen Later May 8, 2025 32:17


Join Dr Sofia Ramiro and cohosts Professors Atul Deodhar, Hideto Kameda, and Xenofon Baraliakos for the latest episode of the discussing axSpA podcast on The Immune-Mediated Inflammatory Disease Forum, where they discuss the latest updates in axSpA. In this episode, our faculty discusses two papers: the first assesses switching to secukinumab or cycling with other TNF inhibitors, and the second investigates long-term safety of bimekizumab in adult patients with axSpA or PsA.

Discussing RA: MACE, VTE, and malignancy in filgotinib RA and UC patients, and MACE related to JAKis

Play Episode Listen Later May 1, 2025 8:31


Join Professor Iain McInnes for the latest episode on The Immune-Mediated Inflammatory Disease Forum, where he discusses the latest updates in RA. In this episode, he discusses two papers: risk of MACE, VTE, and malignancies in patients with RA or UC treated with filgotinib and frequency of reporting of MACE, MI, and stroke between JAKis and anti-TNFα.

Highlights Podcast: IL-17 Inhibition: Controlling inflammation and disease progression in SpA

Play Episode Listen Later Apr 16, 2025 32:21


Highlights Podcast: IL-17 Inhibition: Controlling inflammation and disease progression in SpA by The Immune-Mediated Inflammatory Disease Forum

Discussing PsA: JAKi Comparative safety & Burden and determinants of multi‑b/tsDMARD failure in PsA

Play Episode Listen Later Apr 3, 2025 29:23


Join Professors Laura Coates and Philip Mease as they discuss the top publications in the world of PsA. This month, the conversation covered a discussion on the comparative safety of JAK inhibitors versus TNF or IL-17 inhibitors for cardiovascular disease and cancer in psoriatic arthritis and axial spondyloarthritis. They also give insights into the burden and determinants of multi‑b/tsDMARD failure in psoriatic arthritis.

Discussing RA: Pain reduction & choosing second-line DMARDs after unresponsive first-line DMARDs

Play Episode Listen Later Mar 27, 2025 21:40


Join Professors Iain McInnes and Peter Nash for the latest episode on The Immune-Mediated Inflammatory Disease Forum, where they discuss the latest updates in RA. In this episode, they discuss two papers: effectiveness of JAKi compared with bDMARDs on pain reduction and effective second‑line b/tsDMARD for patients with rheumatoid arthritis unresponsive to first‑line b/tsDMARDs.

Author Interview: Professor Phillip Helliwell, March 2025

Play Episode Listen Later Mar 20, 2025 22:30


Join Professor Peter Nash from the Griffith University in Brisbane, and Professor Phillip Helliwell, Professor of rheumatology at The University of Leeds in the UK, as they discuss ‘Tight Control and Radiological Progression: The Radiographic Outcomes of the TICOPA Study'

Author Interview: Professor Phillip Helliwell, 2025

Play Episode Listen Later Mar 13, 2025 26:36


Author Interview: Professor Phillip Helliwell, 2025 by The Immune-Mediated Inflammatory Disease Forum

PsA Podcast: Bimekizumab improves patient-reported outcomes and work productivity

Play Episode Listen Later Mar 6, 2025 32:04


Join Professors Peter Nash, Philip Mease, and Laura Coates as they discuss the top publications in the world of PsA. This month, the conversation covered a discussion on the longer-term impact of bimekizumab on patient-reported outcomes, health-related QoL, and work productivity in patients with active PsA who were bDMARD-naïve or had an inadequate response to TNFis for up to 1 year.

Discussing axSpA: Long-term safety and efficacy of Bimekizumab results from BE-AGILE & BE-MOBILE 1/2

Play Episode Listen Later Feb 27, 2025 25:05


Join Dr Sofia Ramiro and cohosts Professors Atul Deodhar, Hideto Kameda, and Xenofon Baraliakos for the latest episode of the discussing axSpA podcast on The Immune-Mediated Inflammatory Disease Forum, where they discuss the latest updates in axSpA. In this episode, our faculty discusses two papers both focusing on the long-term safety and efficacy of Bimekizumab in axSpA patients with 5-year results from the BE-AGILE study and its OLE, and the 2-year results from BE-MOBILE 1 and 2.

Discussing RA: Baricitinib dose reduction and switching to bDMARDs vs JAKis

Play Episode Listen Later Feb 27, 2025 11:17


Join Professors Iain McInnes, Hans Bijlsma, and Peter Nash for the latest episode on The Immune-Mediated Inflammatory Disease Forum, where they discuss the latest updates in RA. In this episode, they discuss two papers: baricitinib dose reduction in patients with RA achieving sustained disease control and switching to bDMARDs vs cycling among JAKis in patients with RA who are inadequate responders to JAKis.

Author Interview: Professor Denis McGonagle, 2025

Play Episode Listen Later Feb 6, 2025 36:01


Join Professor Peter Nash from the Griffith University in Brisbane, and Professor Denis McGonagle, Professor of investigative rheumatology at the NIHR funded Academic Unit for the Musculoskeletal Diseases and Leeds Teaching Hospitals NHS Trust in the UK, as they discuss his recent review ‘Subclinical psoriatic arthritis and disease interception—where are we in 2024?'

Discussing RA: Insights into sustained DMARD-free remission and barriers to CAR T-cell therapy

Play Episode Listen Later Jan 23, 2025 11:18


Join Professor Iain McInnes for the latest episode on The Immune-Mediated Inflammatory Disease Forum, where he discusses the latest updates in RA. In this episode, Professor McInnes discusses two papers: subgroups of patients with early RA with or without bDMARD who reached sustained DMARD-free remission and barriers to the widespread adoption of CAR T-cell therapy in rheumatic diseases.

Discussing RA: Insights into Filgotinib and Tofacitinib in RA

Play Episode Listen Later Dec 19, 2024 24:13


Join Professor Iain McInnes and Professor Rieke Alten for the latest episode on The Immune-Mediated Inflammatory Disease Forum, where they discuss the latest updates in RA. In this episode, they discuss two papers which discuss the efficacy and safety of filgotinib, and lymphocyte count and infection risk associated with tofacitinib in rheumatoid arthritis.

Discussing AxSpA Podcast: Efficacy and Safety of Upadacitinib

Play Episode Listen Later Dec 19, 2024 18:42


Join us for the latest axSpA podcast brought to you by the Immune-Mediated Inflammatory Disease Forum! This month, Dr Sofia Ramiro is joined by Professors Hideto Kameda, Atul Deodhar, and Xenfon Baraliakos to discuss a recent study on the efficacy and safety of upadacitinib in patient with ankylosing spondylitis.

PsA Podcast: DISCOVER-2 and BE OPTIMAL/BE COMPLETE post-hoc analyses

Play Episode Listen Later Nov 28, 2024 30:53


Join Professors Peter Nash and Philip Mease as they discuss the top publications in the world of PsA. This month, the conversation covered a post hoc analysis examining the rapid and sustained efficacy of bimekizumab in PsA patients across different subgroups, focusing on improvements in pain, fatigue, and physical function over 16 weeks. The conversation also covered a long-term analysis of guselkumab assessing the durability of clinical improvements in joint and skin symptoms in PsA patients over a 2-year period.

ACR 2024 Review Podcast

Play Episode Listen Later Nov 28, 2024 50:04


ACR 2024 Review Podcast by The Immune-Mediated Inflammatory Disease Forum

Discussing RA: Insights into Filgotinib and Tofacitinib in RA

Play Episode Listen Later Nov 14, 2024 19:16


Join Professor Iain McInnes and Professor Johannes Bijlsma for the latest episode on The Immune-Mediated Inflammatory Disease Forum, where they discuss the latest information and data in RA. In this episode, they discuss two papers which discuss the efficacy and safety of filgotinib, and lymphocyte count and infection risk associated with tofacitinib in rheumatoid arthritis.

Webinar Highlights Podcast: CAR T-cell Therapy: An Emerging Therapy in Autoimmune Diseases

Play Episode Listen Later Nov 13, 2024 26:39


Webinar Highlights Podcast: Join Professor Iain McInnes and Professor Georg Schett as they discuss the recent webinar hosted on the IMID Forum: “CAR T-cell Therapy: An Emerging Therapy in Autoimmune Diseases”. Listen to them discuss key highlights from the webinar including the development of CAR T-cell therapy, the application of CAR T to autoimmune diseases, and the potential risks and reservations associated with this therapeutic approach.

ACR 2024: Preview Podcast

Play Episode Listen Later Nov 11, 2024 19:51


ACR 2024: Preview Podcast by The Immune-Mediated Inflammatory Disease Forum

ACR 2024 Highlights: Day 2

Play Episode Listen Later Nov 11, 2024 3:36


ACR 2024 Highlights: Day 2 by The Immune-Mediated Inflammatory Disease Forum

ACR 2024 Highlights: Day 1

Play Episode Listen Later Nov 11, 2024 2:55


ACR 2024 Highlights: Day 1 by The Immune-Mediated Inflammatory Disease Forum

ACR 2024 Highlights: Day 3

Play Episode Listen Later Nov 11, 2024 4:21


ACR 2024 Highlights: Day 3 by The Immune-Mediated Inflammatory Disease Forum

AxSpA Podcast: Efficacy and Safety of IV secukinumab

Play Episode Listen Later Oct 31, 2024 23:30


Join us for the latest axSpA podcast brought to you by the Immune-Mediated Inflammatory Disease Forum! This month, Dr Sofia Ramiro is joined by Professors Hideto Kameda, and Atul Deodhar to discuss a recent study on the efficacy and safety of IV secukinumab in patient with active axSpA.

Discussing RA: Navigating JAKis, TNFis, and the quest for optimal RA therapy

Play Episode Listen Later Oct 31, 2024 22:03


Join Professor Iain McInnes and Professor Leonard Calabrese for the latest episode on The Immune-Mediated Inflammatory Disease Forum, where they discuss the latest information and data in RA. In this episode, they discuss two papers which investigate the efficacy and safety of JAK inhibitors and TNF inhibitors for rheumatoid arthritis, while also uncovering the best treatment strategies for difficult-to-treat RA.

Author Interview: Derin Karacabeyli, 2024

Play Episode Listen Later Oct 10, 2024 33:27


Join Professor Peter Nash from the Griffith University in Brisbane, and Dr Derin Karacabeyli of Arthritis Research Canada, a rheumatologist and resident in the University of British Columbia Clinician Investigator Program, as they discuss his recent paper ‘Mortality and major adverse cardiovascular events after glucagon-like peptide-1 receptor agonist initiation in patients with immune-mediated inflammatory diseases and type 2 diabetes: A population-based study', published in PLoS One on 08th August 2024.

Webinar Highlights Podcast 2: Evolving Therapeutic Strategies for Psoriatic Diseases

Play Episode Listen Later Oct 7, 2024 32:56


Webinar Highlights Podcast: Join Professor Christopher Ritchlin, and Professor Philip Mease as they discuss the recent webinar hosted on the IMID Forum ‘Evolving Therapeutic Strategies for Psoriatic Diseases: Not all IL-23s are Created Similar - Part 2'. Watch them discuss key highlights from the webinar including the burden of PsA and PsO, the similarities and differences in pathology in skin and joints across psoriatic arthritis, and a special focus on IL-23, and its clinical data and impact across different tissue domains.

PsA Podcast: Bimekizumab: Efficacy, safety, and effectiveness in PsA

Play Episode Listen Later Sep 26, 2024 21:04


Join Professors Peter Nash, Philip Mease, and Laura Coates as they discuss the top publications in the world of PsA. This month, the conversation covered a matching-adjusted indirect comparison (MAIC) to assess the comparative efficacy of bimekizumab and risankizumab in patients with psoriatic arthritis over 52 weeks, and a post hoc analysis investigating the efficacy and safety of bimekizumab in PsA patients with or without concomitant methotrexate over 52 weeks.

Discussing RA: Long-term safety and efficacy of upadacitinib in SELECT trials

Play Episode Listen Later Sep 19, 2024 19:24


Join Professor Iain McInnes and Professors Hideto Kameda and Rieke Alten for the latest episode on The Immune-Mediated Inflammatory Disease Forum, where they discuss the latest information and data in RA. In this episode, they discuss two papers which investigate the long-term efficacy and safety of upadacitinib in the SELECT trials.

Discussing AxSpA: Incidence of uveitis following bimekizumab treatment

Play Episode Listen Later Aug 29, 2024 24:11


Join us for the latest axSpA podcast brought to you by the Immune-Mediated Inflammatory Disease Forum! This month, Dr Sofia Ramiro is joined by Professors Hideto Kameda, Atul Deodhar, and Xenofon Baraliakos to discuss a recent study on the incidence of uveitis in patients with axSpA that were treated with bimekizumab.

Author Interview: Professor Laura Andreoli, 2024

Play Episode Listen Later Aug 22, 2024 44:09


Join Professor Peter Nash from the Griffith University in Brisbane, and Professor Laura Andreoli, a Professor of Rheumatology at the University of Brescia, as they discuss her recent paper ‘The outcomes of children born to mothers with autoimmune rheumatic diseases', published in The Lancet. Rheumatology on 11th June 2024.

Discussing RA: Neutrophil-to-lymphocyte ratio and treatment response to filgotinib

Play Episode Listen Later Aug 15, 2024 16:05


Join Professor Iain McInnes and Professors Hideto Kameda and Peter Nash for the latest episode on The Immune-Mediated Inflammatory Disease Forum, where they discuss the latest information and data in RA. In this episode, they discuss a paper that investigated whether the baseline neutrophil-to-lymphocyte ratio had an effect on the treatment response to filgotinib.

Author Interview: Dr Adam Goldman, 2024

Play Episode Listen Later Aug 8, 2024 21:07


Join Professor Peter Nash from the Griffith University in Brisbane, and Dr Adam Goldman, an epidemiology researcher at The Chaim Sheba Medical Center in Tel-Hashomer, and an epidemiology researcher and lecturer at Tel-Aviv University, as they discuss his recent paper ‘Adverse cardiovascular events in rheumatoid arthritis patients treated with JAK inhibitors: An analysis of postmarketing spontaneous safety reports', published in Seminars in Arthritis and Rheumatism on 17th May 2024.

Author Interview: Professor Daniel Blockmans, 2024

Play Episode Listen Later Jul 25, 2024 26:44


Join Professor Peter Nash from the Griffith University in Brisbane, and Professor Daniel Blockmans, from the Department of Internal Medicine at the University Hospitals Leuven, as they discuss his recent paper ‘Efficacy and safety of upadacitinib in patients with giant cell arteritis (SELECT-GCA): A double-blind, randomized controlled Phase 3 trial', published in Annals of the Rheumatic Diseases on June 2024.

PsA Podcast: Guselkumab and analysis of genetic markers

Play Episode Listen Later Jul 25, 2024 25:46


Join Professors Peter Nash, Philip Mease, and Laura Coates as they discuss the top publications in the world of PsA. This month, the conversation covered the post hoc analysis of PsA patients receiving guselkumab, focusing on disease control across domains and patient characteristics, and a systematic review and meta-analysis on genetic markers and their response to biologics in inflammatory diseases.

Discussing RA: July 2024

Play Episode Listen Later Jul 18, 2024 23:23


Join Professor Iain McInnes and guest Professor Maurizio Cutolo for the latest episode on The Immune-Mediated Inflammatory Disease Forum, where they discuss the latest information and data in RA. In this episode, two papers that cover important topics in rheumatology are highlighted: the first paper presents the 5-year efficacy and safety results of upadacitinib in RA, while the second provides an overview of the literature and guidance on discussing outcomes regarding children born of mothers with autoimmune rheumatic diseases.

AxSpA Podcast: Upadacitinib in nr-axSpA and certolizumab pegol by baseline MRI and CRP status

Play Episode Listen Later Jul 4, 2024 22:14


Join us for the latest axSpA podcast brought to you by the Immune- ediated Inflammatory Disease Forum! This month, Dr Sofia Ramiro is joined by Professors Hideto Kameda and Xenofon Baraliakos to discuss the results of a Phase 3 trial on upadacitinib in nr-axSpA and the clinical outcomes of certolizumab pegol treatment in nr-axSpA stratified by baseline MRI and CRP status.

Discussing RA: June 2024

Play Episode Listen Later Jun 27, 2024 25:59


Join Professors Iain McInnes, Peter Nash, and Maurizio Cutolo for the latest episode on The Immune-Mediated Inflammatory Disease Forum, where they discuss the latest information and data in RA. In this episode they discuss two papers, one that investigated the long-term safety of filgotinib in moderate-to-severe RA, and the other a postmarketing analysis of adverse cardiovascular events with JAKi treatments in RA.

EULAR 2024 Review Podcast

Play Episode Listen Later Jun 19, 2024 36:38


Join Dr Sofia Ramiro, Professor Rieke Alten, and Associate Professor Laura Coates as they review their top sessions in RA, PsA, and axSpA from EULAR 2024, providing insight into how these data will shape clinical practice going forward.

EULAR 2024 Highlights: Day 4

Play Episode Listen Later Jun 15, 2024 2:44


Join Dr Sofia Ramiro as she summarises her top abstracts, posters, and presentations from Day 1 of EULAR 2024 (Saturday, June 15).

EULAR 2024 Highlights: Day 3

Play Episode Listen Later Jun 14, 2024 4:25


Join Dr Sofia Ramiro as she summarises her top abstracts, posters, and presentations from Day 3 of EULAR 2024 (Friday, June 14).

EULAR 2024 Highlights: Day 2

Play Episode Listen Later Jun 13, 2024 4:00


Join Dr Sofia Ramiro as she summarises her top abstracts, posters, and presentations from Day 2 of EULAR 2024 (Thursday, June 13).

EULAR 2024 Highlights: Day 1

Play Episode Listen Later Jun 12, 2024 5:09


Join Dr Sofia Ramiro as she summarises her top abstracts, posters, and presentations from Day 1 of EULAR 2024 (Wednesday, June 12).

EULAR 2024 Preview Podcast

Play Episode Listen Later Jun 10, 2024 14:00


Join Dr Sofia Ramiro, Professor Rieke Alten, and Associate Professor Laura Coates as they guide you through their top selections in RA, PsA, and axSpA at EULAR 2024, so that you can better plan your time at what will be a busy and exciting congress.

Discussing RA: May 2024

Play Episode Listen Later Jun 6, 2024 30:08


Join Professor Iain McInnes and guests Professor Janet Pope and Dr Sofia Ramiro for the latest episode on The Immune-Mediated Inflammatory Disease Forum, where he discusses the latest information and data in RA. In this episode, he discusses two papers that investigated the long-term safety of JAK inhibitors from Phase 3 trials. In our first paper, Maya Buch and colleagues examined extended MACE endpoints with tofacitinib versus TNFi. Our second paper is from Gerd Burmester and colleagues present long-term efficacy and safety data for upadacitinib through five years. To access detailed summary slides for the papers discussed today, visit imidforum.com.

PsA Podcast: Bimekizumab therapy in PsA

Play Episode Listen Later May 30, 2024 29:49


Join Professors Peter Nash, Philip Mease, and Laura Coates as they discuss the top publications in the world of PsA. This month, they focus the latest publication by Su, et al. as well as discuss all the latest in for bimekizumab therapy in PsA.

IMID Author Interview: Dr Blanca Hernández-Cruz, 2024

Play Episode Listen Later May 28, 2024 33:50


Join Professor Peter Nash from the Griffith University in Brisbane, and Blanca Hernández-Cruz, a rheumatologist at Virgen Macarena University Hospital in Seville, as they discuss her recent paper ‘Janus kinase inhibitors and tumour necrosis factor inhibitors show a favourable safety profile and similar persistence in rheumatoid arthritis, psoriatic arthritis and spondyloarthritis: real-world data from the BIOBADASER registry'.

IMID Author Interview: Dorthe Berthelsen, 2024

Play Episode Listen Later May 14, 2024 23:26


Join Professor Peter Nash from the Griffith University in Brisbane, and Dorthe Berthelsen, a PhD student and physiotherapist at the Parker Institute in Copenhagen and at the University of Southern Denmark, as they discuss her recent paper ‘“I couldn't carry on taking a drug like that”: A qualitative study of patient perspectives on side effects from rheumatology drugs.'

AxSpA Podcast: Long-term etanercept response & real-world effectiveness of tofacitinib & adalimumab

Play Episode Listen Later May 9, 2024 29:48


Join us for the latest axSpA podcast brought to you by the Immune-mediated Inflammatory Disease forum! This month, Dr Sofia Ramiro is joined by Professors Hideto Kameda, Atul Deodhar and Xenofon Baraliakos to discuss the long-term etanercept response in patients with radiographic axSpA and the comparison of tofacitinib and adalimumab in a real-world clinical context.

Webinar Highlights Podcast: Evolving Therapeutic Strategies for Psoriatic Diseases

Play Episode Listen Later May 7, 2024 29:42


Webinar Highlights Podcast: Join Professor Iain McInnes and Associate Professor Laura Coates on the Immune-Mediated Inflammatory Disease Forum in their discussion on the recent webinar “Evolving Therapeutic Strategies for Psoriatic Diseases: Not all IL-23s are Created Similar”. Watch them discuss key highlights from the webinar including the burden of PsA and PsO, the pathophysiology of IL-23 inhibitors compared with TNF and IL-17 inhibitor therapies, and the relationship between IL-23 inhibitor MOA variation and real-world patient data.

IMID Author Interview: Dr Jake Weddell, 2024

Play Episode Listen Later May 7, 2024 21:01


Join Professor Peter Nash from the Griffith University in Brisbane, and Dr Jake Weddell, an academic rheumatology trainee at Leeds Teaching Hospitals NHS Trust, as they discuss his recent paper ‘Abatacept Inhibits Inflammation and Onset of Rheumatoid Arthritis in Individuals at High Risk (ARIAA): A Randomised, International, Multicentre, Double-blind, Placebo-controlled Trial.'

PsA Podcast: 2023 EULAR recommendations and improvements in PROs with deucravacitinib

Play Episode Listen Later May 2, 2024 28:33


Join Professors Peter Nash, Philip Mease, and Laura Coates as they discuss the top publications in the world of PsA. This month, they focus on the updated 2023 EULAR recommendations for PsA and the improvement of PROs reported in a Phase 2 trial with deucravacitinib.

Claim Cytokine Signalling Forum

In order to claim this podcast we'll send an email to with a verification link. Simply click the link and you will be able to edit tags, request a refresh, and other features to take control of your podcast page!

Claim Cancel